Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

May 5, 2023

Study Completion Date

May 5, 2023

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

Experimental 23-valent Pneumococcal

The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.

Trial Locations (2)

034199

The First People's Hospital of Yuanping Medical Group, Yuanping

044000

Salt Lake District Center for Disease Control and Prevention, Yuncheng

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY